AcquisitionSep 21, 2026Pending
🇩🇪 Germany
IIITM Isotope Technologies Munich SETPTelix Pharmaceuticals Limited
Healthcare › Biotechnology
Enterprise value$1.65BEnterprise value
AnnouncedSep 21, 2026
ConsiderationCash and stock
StructureOther
RegionEurope
Cross-borderYes
Contingent paymentYes
Overview
Telix Pharmaceuticals Limited agreed to acquire ITM Isotope Technologies Munich SE for US$1.65 billion upfront on a cash-free/debt-free basis, with US$1.25 billion payable in Telix shares and up to US$700 million in contingent milestone payments.
Deal rationale
The merger is intended to create a vertically integrated radiopharmaceutical company with enhanced isotope production, manufacturing capabilities, and a late-stage therapeutic pipeline.
AI-generated from the SEC filingPendingHealthcare › BiotechnologyGermanyEurope
Timeline
Valuation and terms
| Equity value | $1.25B | |
|---|---|---|
| Enterprise value | $1.65B | Headline figure |
| Consideration | Cash and stock |
Advisors
Buy-side
None listed
Sell-side
CPCenterview Partners
Parties
Target
IIITM Isotope Technologies Munich SE
- Headquarters
- Germany
- Ticker
- —
Acquirer
TPTelix Pharmaceuticals Limited
- Headquarters
- Australia
- Ticker
- —